Abstract 3922
Background
Currently cancer patients treated with immune checkpoint modulators (ICMs) have their health related quality of life (HRQOL) measured by general patient reported outcome (PRO) tools such as the EORTC QLQC30 or Functional Assessment of Cancer Therapy-General (FACT-G). No instrument has been developed specifically for patients treated with ICMs, which may lead to their HRQOL being evaluated inaccurately. The objective of this study was to develop a toxicity subscale PRO instrument for ICM treated patients that would contribute to the measurement of HRQOL.
Methods
Input was collected from a prior systematic review, patients and physicians. Descriptive thematic analysis was used to evaluate the qualitative data obtained from patient focus groups and interviews, which informed the development of an initial list of items that described ICM side effects (SEs) and their impacts upon HRQOL. Physician surveys and interviews informed subsequent item generation/reduction. Cognitive debriefing interviews were conducted with a new set of patients after they completed the toxicity subscale.
Results
Focus groups and individual interviews with 37 ICM-treated patients generated an initial list of 176 items. Following a first round of item reduction that produced a shortened list of 76 items, 16 physicians who care for ICM treated patients were surveyed with a list of 49 patient reported toxicity related unique SEs; and 11 physicians participated in follow up interviews. Informed by the data collected from the physicians, a second round of item reduction produced a list of 25 items that covered a wide range of SEs including but not limited to gastrointestinal, cutaneous, musculoskeletal, respiratory, constitutional, neurological and endocrine. This final list was piloted with 11 patients who confirmed that it was comprehensible and complete.
Conclusions
This 25 item list is the first HRQOL toxicity subscale developed with patient and clinician input for patients treated with ICMs. The subscale will be combined with the FACT-G to form the FACT-ICM and this PRO instrument will undergo further validity testing.
Clinical trial identification
NCT02651831.
Editorial acknowledgement
Legal entity responsible for the study
Princess Margaret Cancer Centre.
Funding
University of Toronto, Strategic Innovation Grant.
Disclosure
A.R. Hansen: Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): GSK; Advisory / Consultancy, Research grant / Funding (institution): Roche-Genentech; Advisory / Consultancy, Research grant / Funding (institution): MedImmune; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Boston Biomedical; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb. P. Bedard: Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Genentech/Roche; Research grant / Funding (institution): Servier; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): SignalChem; Research grant / Funding (institution): PTC Therapeutics; Research grant / Funding (institution): Nektar; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Seattle Genetics; Research grant / Funding (institution): Mersana; Research grant / Funding (institution): Immunomedics; Research grant / Funding (institution): Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
2888 - Development and validation a nomogram based on pathological microscopic features to predict survival in nasopharyngeal carcinoma and guide treatment decision
Presenter: Kuiyuan Liu
Session: Poster Display session 3
Resources:
Abstract
3607 - Deep learning in nasopharyngeal carcinoma: a retrospective cohort study of 3D convolutional neural networks on magnetic resonance imaging
Presenter: Meng Yun Qiang
Session: Poster Display session 3
Resources:
Abstract
5848 - Combined androgen blockade in patients with advanced androgen receptor–positive salivary gland carcinoma: Exploratory biomarker analyses
Presenter: Chihiro Fushimi
Session: Poster Display session 3
Resources:
Abstract
4484 - Classification of esthesioneuroblastoma (ENB) based on chromosome (chr) arm gain and loss (CNA) in the setting of a hypomutated genomic landscape
Presenter: Russell Madison
Session: Poster Display session 3
Resources:
Abstract
5753 - Trastuzumab plus docetaxel in patients with advanced HER2–positive salivary duct carcinoma: Exploratory biomarker analyses
Presenter: Hideaki Takahashi
Session: Poster Display session 3
Resources:
Abstract
3373 - Development and characterization of salivary gland cancer organoid cultures
Presenter: Wim Boxtel
Session: Poster Display session 3
Resources:
Abstract
3118 - A parent-of-origin effect of the RB1 mutations in retinoblastoma with low penetrance and variable expressivity
Presenter: Ekaterina Alekseeva
Session: Poster Display session 3
Resources:
Abstract
4512 - The humanistic burden reported by patients diagnosed with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) in Europe
Presenter: Prianka Singh
Session: Poster Display session 3
Resources:
Abstract
3961 - Concurrent Chemotherapy and External Radiation Therapy: An Open Label Non-Inferiority Phase III Randomized Controlled Trial of Weekly versus Three Weekly Cisplatin and Radical Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: CONCERT trial
Presenter: ATUL SHARMA
Session: Poster Display session 3
Resources:
Abstract
3973 - A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck (SCCHN) – OPTIM (AIO-KHT-0117)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract